Aktis Oncology, Inc. cash flow to debt ratio of -555.31% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aktis Oncology, Inc.'s free cash flow has decreased 719.42% from $11.90M last year to $-73.71M, signaling decreasing performance

Aktis Oncology, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Aktis Oncology, Inc.'s debt has increased relative to shareholder equity from -0.14 last year to 0.02 today, signaling weakened financials

Aktis Oncology, Inc. has a net cash position, so leverage is healthy.

Aktis Oncology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Aktis Oncology, Inc.'s profit margin has increased (-77.80%) in the last year from -2.96K% to -656.52%, signaling increasing performance

Aktis Oncology, Inc.'s short-term assets of $230.31M exceed its short-term liabilities of $31.24M

Aktis Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aktis Oncology, Inc.'s return on equity of -44.11%, is lower than 15.00%, indicating bad performance

Aktis Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aktis Oncology, Inc. has insufficient public price history to evaluate earnings stability.

Aktis Oncology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aktis Oncology, Inc. has negative free cash flow, indicating cash burn

Aktis Oncology, Inc.'s yearly earnings has decreased 44.91% since last year from $-43.98M to $-63.73M, signaling decreasing performance

Aktis Oncology, Inc.'s yearly revenue has increased 336.92% since last year from $1.49M to $6.50M, signaling increasing performance

ROIC -7.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aktis Oncology, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Aktis Oncology, Inc. has insufficient public price history to evaluate revenue consistency.

Aktis Oncology, Inc. has insufficient public price history to evaluate ROE consistency.

Aktis Oncology, Inc. has insufficient data to evaluate this check.

Aktis Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aktis Oncology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aktis Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aktis Oncology, Inc. has insufficient data to evaluate this check.

Aktis Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aktis Oncology, Inc. has a price-to-book ratio of 2.63x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aktis Oncology, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue